News Releases Year None2019201820172016 BridgeBio Pharma Reports Third Quarter 2019 Financial Results and Highlights Portfolio Progress 11.07.2019 BridgeBio Pharma Gene Therapy Subsidiaries Present Data Demonstrating Potential in Two Rare Disease Indications at the European Society of Gene and Cell Therapy Conference 10.22.2019 QED and Parent Company BridgeBio Announce Preclinical Data Supporting Tolerability and Activity of Low-dose Infigratinib in Treating Achondroplasia 10.17.2019 BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics 10.14.2019 Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options 09.24.2019 Alexion And BridgeBio Announce Japanese License Agreement For Eidos’ Transthyretin Amyloidosis (ATTR) Investigational Medicine 09.09.2019 BridgeBio Pharma’s Origin Biosciences Presents New Data on the Natural History of Molybdenum Cofactor Deficiency (MoCD) Type A at the Society of the Study of Inborn Errors of Metabolism (SSIEM) Conference 09.05.2019 BridgeBio Pharma expands its research into neuromuscular disease to include Limb-Girdle Muscular Dystrophy Type 2 (LGMD2i) with new subsidiary ML Bio Solutions 09.05.2019 BridgeBio Pharma Announces Pricing of Its Initial Public Offering 06.26.2019 BridgeBio Pharma Announces Filing Of Registration Statement For Proposed Initial Public Offering 05.24.2019 Eidos Therapeutics Initiates Attribute-CM, A Phase 3 Study Of AG10 In ATTR-CM With Registrational 12-Month Endpoint 02.27.2019 Phoenix Tissue Repair Doses First Patient In Phase 1/2 Clinical Trial Of PTR-01 (BBP-589) For Treatment Of Recessive Dystrophic Epidermolysis Bullosa (RDEB) 02.22.2019 BridgeBio Pharma Closes $299.2 Million Financing Round To Support Its Efforts To Target Genetic Disease At The Source 01.23.2019 Eidos Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference 01.02.2019
